GSA Capital Partners’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $441K | Buy |
+38,839
| New | +$441K | 0.03% | 1010 |
|
|
2024
Q2 | – | Sell |
-97,508
| Closed | -$1.32M | – | 2009 |
|
|
2024
Q1 | $1.32M | Sell |
97,508
-4,599
| -5% | -$62.1K | 0.1% | 278 |
|
|
2023
Q4 | $537K | Sell |
102,107
-245,962
| -71% | -$1.29M | 0.05% | 749 |
|
|
2023
Q3 | $1.37M | Buy |
348,069
+291,443
| +515% | +$1.15M | 0.12% | 255 |
|
|
2023
Q2 | $602K | Buy |
56,626
+16,262
| +40% | +$173K | 0.06% | 627 |
|
|
2023
Q1 | $336K | Sell |
40,364
-31,208
| -44% | -$260K | 0.03% | 957 |
|
|
2022
Q4 | $661K | Sell |
71,572
-3,555
| -5% | -$32.8K | 0.08% | 431 |
|
|
2022
Q3 | $965K | Buy |
+75,127
| New | +$965K | 0.13% | 176 |
|
|
2022
Q2 | – | Sell |
-40,495
| Closed | -$852K | – | 1779 |
|
|
2022
Q1 | $852K | Buy |
40,495
+16,028
| +66% | +$337K | 0.11% | 240 |
|
|
2021
Q4 | $587K | Buy |
24,467
+14,714
| +151% | +$353K | 0.07% | 503 |
|
|
2021
Q3 | $248K | Buy |
+9,753
| New | +$248K | 0.03% | 1125 |
|